Dhurandhar 2 Day 2 BMS Sales: Ranveer Singh Fails To Touch Pushpa 2 Yet Again! (Photo Credit: Instagram/Jio Studios) Ranveer Singh is overpowering every Bollywood record in sight, but Allu Arjun’s ...

According to the data, Dhurandhar 2 sold 109k tickets within last one hour on the platform, a number that reflects the sheer craze surrounding the film. Previously, Pushpa 2 had sold 107k tickets in ...

Should you have feedback on this article, please complete the fields below. Please indicate if your feedback is in the form of a letter to the editor that you wish to have published. If so, please be ...

ORION Resource Partners has closed its fourth mine finance fund at approximately $2.2bn, making it the largest vehicle the specialist mining financier has launched to date. The latest fund comes as ...

March 16 (Reuters) - Orion Resource Partners LP said on Monday it has raised about $2.2 billion for its latest mine finance fund, as investors ramp up funding for projects ‌producing critical minerals ...

Orion Resource Partners has raised about $2.2 billion for a new fund dedicated to financing the construction and acquisition of mining projects, as the firm seeks to help governments secure supplies ...

In a dizzying span of seven months in 2022, Bristol Myers Squibb gained FDA approval for three new products, touting each with the potential to achieve $4 billion in peak sales. While multiple myeloma ...

Border 2 Box Office Day 9: Sunny Deol’s 2nd Saturday Ready To Bombard! (Photo Credit: T-Series) While Border 2, with 186K ticket sales on the second Friday, currently sits below the likes of Gadar 2 ...

The Space Launch System rocket and Orion spacecraft make their way to Launch Complex 39B Jan. 17. Credit: SpaceNews/Jeff Foust Updated 8:15 p.m. Eastern with arrival at the launch pad. KENNEDY SPACE ...

Here you are in this great, vast wilderness with untold potential for Doing Things — and you can't do a damn one of them. You can ride a horse in a straight line, and then you can do it again. There's ...

Bristol Myers Squibb is shedding two clinical programs from its in-house pipeline, one from its 2023 Mirati buyout and another from a partnership with U.K. biotech Exscientia, now known as Recursion.